Denne siden ble automatisk oversatt og nøyaktigheten av oversettelsen er ikke garantert. Vennligst referer til engelsk versjon for en kildetekst.

VITAL: Real-World Evaluation of Amlodipine/Valsartan. (VITAL)

24. september 2026 oppdatert av: VIVA PHARM LLP

Evaluation of Clinical Effectiveness in Real-World Clinical Practice, as Well as the Safety and Adherence to Therapy With a Fixed-Dose Combination of Amlodipine and Valsartan

The goal of this observational study is to evaluate the effectiveness, safety, and treatment adherence of a fixed-dose combination of amlodipine and valsartan in adults with grade 2-3 hypertension in real-world clinical practice in Kazakhstan. The study will include patients who have already been prescribed the fixed-dose combination of amlodipine and valsartan (Agvistat®) by their treating physician as part of routine medical care, independently of their participation in the study.

The main questions it aims to answer are:

What proportion of participants achieve the target blood pressure after 12 weeks of treatment with the fixed-dose combination of amlodipine and valsartan? How well do participants adhere to treatment, and what patient characteristics are associated with treatment adherence? What changes occur in blood pressure, heart rate, quality of life, and selected laboratory measures during the 12-week observation period? What adverse events occur during treatment?

Participants will:

Have their clinical and demographic information and data from routine medical care recorded during the study.

Have blood pressure, heart rate, and other relevant clinical data assessed during the 12-week observation period.

Complete questionnaires assessing treatment adherence and quality of life. Participate in follow-up visits at 4, 8, and 12 weeks; the 4- and 8-week visits will be conducted remotely, while the enrollment and 12-week visits will be conducted at the study site.

Studieoversikt

Status

Aktiv, ikke rekrutterende

Forhold

Intervensjon / Behandling

Studietype

Observasjonsmessig

Registrering (Faktiske)

216

Kontakter og plasseringer

Denne delen inneholder kontaktinformasjon for de som utfører studien, og informasjon om hvor denne studien blir utført.

Studiesteder

  • Kasakhstan
      • Aktobe, Kasakhstan
        • 'Kuanysh' LLP Health Centre
      • Aktobe, Kasakhstan
        • 'Phoenix Hospital' LLP
      • Aktobe, Kasakhstan
        • Sara Clinic Medical Centre LLP
      • Almaty, Kasakhstan
        • "Medical Assistance Group" LLP
      • Almaty, Kasakhstan
        • 'Vector Vita' Medical Centre LLP
      • Almaty, Kasakhstan
        • State-owned Enterprise for Public Health 'National Hospital of the Medical Centre of the Presidential Administration of the Republic of Kazakhstan'
      • Astana, Kasakhstan
        • "Green Clinic" LLP
      • Astana, Kasakhstan
        • "Kazakhstan Social and Medical Company 'ZHANYA' LLP"
      • Astana, Kasakhstan
        • State-owned Enterprise 'Hospital of the Medical Centre of the Presidential Administration of the Republic of Kazakhstan'
      • Shymkent, Kasakhstan
        • "Clinic DL-ECO" LLP
      • Shymkent, Kasakhstan
        • "Esculap-Vita" LLP
      • Shymkent, Kasakhstan
        • "OrkenMed" LLP
      • Shymkent, Kasakhstan
        • 'Ai-Nury' Medical Centre LLP
      • Ust-Kamenogorsk, Kasakhstan
        • 'GaMMA' Clinical and Diagnostic Centre LLP
      • Ust-Kamenogorsk, Kasakhstan
        • State Communal Enterprise on the Right of Economic Management "East Kazakhstan Regional Hospital
      • Ust-Kamenogorsk, Kasakhstan
        • The 'Outpatient Centre' organisation
    • Turkistan Oblast
      • Shymkent, Turkistan Oblast, Kasakhstan
        • "Medical Center Shubarsu" LLP
      • Turkestan, Turkistan Oblast, Kasakhstan
        • "Clinic of Doctor Irsaliev N.R." LLP

Deltakelseskriterier

Forskere ser etter personer som passer til en bestemt beskrivelse, kalt kvalifikasjonskriterier. Noen eksempler på disse kriteriene er en persons generelle helsetilstand eller tidligere behandlinger.

Kvalifikasjonskriterier

Alder som er kvalifisert for studier

18 år og eldre (Voksen, Eldre voksen)

Tar imot friske frivillige

Nei

Kjønn som er kvalifisert for studier

Alle

Prøvetakingsmetode

Ikke-sannsynlighetsprøve

Studiepopulasjon

The study population will consist of adult male and female patients aged ≥18 years with a confirmed diagnosis of grade 2-3 hypertension who have been prescribed a fixed-dose combination of amlodipine and valsartan (Agvistat®) by their treating physician as part of standard clinical practice, independently of participation in the study. The study will include patients with a medical history indicating failure to achieve target blood pressure while receiving a free combination of antihypertensive drugs. A total of 216 participants will be enrolled and observed for up to 12 weeks.

Beskrivelse

Inclusion Criteria:

  1. Male or female participants aged ≥18 years at the time of enrollment.
  2. Signed and dated written informed consent in accordance with ICH GCP and applicable local legislation before enrollment in the study.
  3. Women of childbearing potential must use an adequate method of contraception throughout the study.
  4. Documented diagnosis of grade 2-3 hypertension according to current clinical guidelines for hypertension, defined as systolic blood pressure (SBP) ≥140 mmHg and/or diastolic blood pressure (DBP) ≥90 mmHg measured at two different visits.
  5. Treatment with a fixed-dose combination of amlodipine and valsartan (Agvistat®) prescribed by the treating physician as part of standard clinical practice before enrollment, independently of participation in this study.
  6. Medical history indicating failure to achieve target blood pressure while receiving a free combination of antihypertensive drugs.

Exclusion Criteria:

  1. Participation in any randomized controlled trial within 3 months before enrollment in this study or during participation in this study.
  2. Atrial fibrillation; severe chronic heart failure (NYHA functional class III-IV or left ventricular ejection fraction ≤40% by echocardiography); or acute coronary syndrome or acute cerebrovascular event within the previous year.
  3. Secondary hypertension.
  4. Contraindications or conditions requiring caution listed in the prescribing information for the fixed-dose combination of amlodipine and valsartan, including: hypersensitivity to the active substances, other dihydropyridine derivatives, or any excipients; severe hepatic impairment, biliary cirrhosis, or cholestasis; concomitant use of aliskiren-containing medicinal products in patients with diabetes mellitus or renal impairment (eGFR <60 mL/min/1.73 m²); second or third trimester of pregnancy; severe hypotension; shock, including cardiogenic shock; left ventricular outflow tract obstruction, including hypertrophic obstructive cardiomyopathy or severe aortic stenosis; and hemodynamically unstable heart failure following acute myocardial infarction.

Studieplan

Denne delen gir detaljer om studieplanen, inkludert hvordan studien er utformet og hva studien måler.

Hvordan er studiet utformet?

Designdetaljer

  • Observasjonsmodeller: COHORT
  • Tidsperspektiver: PROSPECTIVE

Kohorter og intervensjoner

Gruppe / Kohort
Intervensjon / Behandling
Amlodipine/valsartan-treated cohort

Adults with grade 2-3 hypertension who have been prescribed a fixed-dose combination of amlodipine and valsartan (Agvistat®) by their treating physician as part of routine clinical practice, independently of participation in the study. Participants are observed for up to 12 weeks to assess treatment effectiveness, adherence, safety, blood pressure control, and quality of life.
Legemiddel: Amlodipine / Valsartan

Fixed-dose combination of amlodipine and valsartan administered as part of routine clinical practice. The treatment is prescribed by the treating physician independently of study participation. The study does not assign treatment or provide the study drug. The available doses are amlodipine 5 mg/valsartan 160 mg and amlodipine 10 mg/valsartan 160 mg, administered once daily.

Hva måler studien?

Primære resultatmål

Resultatmål
Tiltaksbeskrivelse
Tidsramme
Proportion of participants achieving target blood pressure at 12 weeks
Tidsramme: 12 weeks

Proportion of participants who achieve the target blood pressure after 12 weeks of therapy: <140/90 mmHg for the general population or <130/80 mmHg for participants at high cardiovascular risk and participants younger than 60 years.
12 weeks

Sekundære resultatmål

Resultatmål
Tiltaksbeskrivelse
Tidsramme
Association between treatment adherence and clinical and demographic characteristics
Tidsramme: 12 weeks

Association between treatment adherence, assessed using the Morisky-Green scale, and clinical and demographic characteristics of participants, including age, sex, comorbidities, and duration of hypertension.
12 weeks
Change in heart rate from baseline
Tidsramme: 12 weeks

Change in heart rate from baseline during the observation period.
12 weeks
Change in alanine aminotransferase (ALT) from baseline
Tidsramme: 12 weeks

Change in alanine aminotransferase (ALT) level from baseline during the observation period.
12 weeks
Change in aspartate aminotransferase (AST) from baseline
Tidsramme: 12 weeks

Change in aspartate aminotransferase (AST) level from baseline during the observation period.
12 weeks
Change in serum creatinine from baseline
Tidsramme: 12 weeks

Change in serum creatinine level from baseline during the observation period.
12 weeks
Change in blood glucose from baseline
Tidsramme: 12 weeks

Change in blood glucose level from baseline during the observation period.
12 weeks
Change in low-density lipoprotein cholesterol from baseline
Tidsramme: 12 weeks

Change in low-density lipoprotein cholesterol (LDL-C) level from baseline during the observation period.
12 weeks
Change in body mass index from baseline
Tidsramme: 12 weeks

Change in body mass index (BMI) from baseline during the observation period.
12 weeks
Change in EQ-5D quality of life score
Tidsramme: 12 weeks

Change in the score of the standardized EQ-5D quality of life questionnaire during the observation period.
12 weeks
Association of clinical and demographic factors with achievement of target blood pressure
Tidsramme: 12 weeks

Association of clinical and demographic factors, including diabetes mellitus, obesity, grade of hypertension, chronic heart failure, age, and sex, with achievement of target blood pressure at 12 weeks of therapy.
12 weeks
Patient satisfaction with treatment
Tidsramme: 12 week

Assessment of participants' satisfaction with treatment using a 5-point Likert scale.
12 week
Frequency and characteristics of adverse drug reactions
Tidsramme: 12 weeks

Frequency and characteristics of adverse drug reactions associated with the use of the fixed-dose combination of amlodipine and valsartan, identified based on the analysis of adverse reaction reports (Yellow Cards).
12 weeks

Samarbeidspartnere og etterforskere

Det er her du vil finne personer og organisasjoner som er involvert i denne studien.

Sponsor

VIVA PHARM LLP

Studierekorddatoer

Disse datoene sporer fremdriften for innsending av studieposter og sammendragsresultater til ClinicalTrials.gov. Studieposter og rapporterte resultater gjennomgås av National Library of Medicine (NLM) for å sikre at de oppfyller spesifikke kvalitetskontrollstandarder før de legges ut på det offentlige nettstedet.

Studer hoveddatoer

Studiestart (Faktiske)

20. november 2025

Primær fullføring (Antatt)

20. september 2026

Studiet fullført (Antatt)

20. november 2026

Datoer for studieregistrering

Først innsendt

14. september 2026

Først innsendt som oppfylte QC-kriteriene

24. september 2026

Først lagt ut (Faktiske)

29. september 2026

Oppdateringer av studieposter

Sist oppdatering lagt ut (Faktiske)

29. september 2026

Siste oppdatering sendt inn som oppfylte QC-kriteriene

24. september 2026

Sist bekreftet

1. september 2026

Mer informasjon

Begreper knyttet til denne studien

Nøkkelord

Ytterligere relevante MeSH-vilkår

Andre studie-ID-numre

  • VP-01

Plan for individuelle deltakerdata (IPD)

Planlegger du å dele individuelle deltakerdata (IPD)?

NEI

Legemiddel- og utstyrsinformasjon, studiedokumenter

Studerer et amerikansk FDA-regulert medikamentprodukt

Nei

Studerer et amerikansk FDA-regulert enhetsprodukt

Nei

Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .

Abonnere